Getting the CMC regulatory aspects for your oligonucleotide therapeutic right from the outset?
Oligos find themselves in an unusual regulatory situation. Some of the standard ICH guidelines do not fully apply.
Ardena’s CMC regulatory team has gained substantial experience in this field and guides you through the regulatory framework to speed up the time to clinic.
Access the full info sheet here.
